Kevin Sarney, Finance lead
Kevin has over 20 years of experience in public and private life science companies and professional services. He utilizes his experiences to assist companies in the preparation and completion of financial raises, public company readiness, financial controls, audits, SEC reporting and supporting financial operations from drug development through pharmaceutical product launches.
Kevin’s professional career began in Big 4 public accounting. He has held leadership positions at public biotech companies and private early-stage drug development companies. Kevin has numerous experiences in assisting companies going public at Enumeral, Tesaro, Tetraphase, Karyopharm, and Genocea. Kevin earned a B.S. in business management from the University of Hartford, an MBA from Boston University, and an M.A. in accounting from Suffolk University. Kevin is a CPA in Massachusetts.
Robert Schaub Ph.D, Chief Scientific Officer
Dr. Schaub has over 40 years experience as a scientific leader and senior executive with success in the development of small molecules, therapeutic proteins, aptamers and devices. He has held significant decision making roles leading groups responsible for 15 INDs including drugs for sickle cells disease, hemophilia, thrombosis, bone growth, oncology, inflammation and infectious disease. Several of these were first in class. Four of these programs resulted in market approval. These were recombinant Factor IX (BeneFIX®), recombinant Interleukin-11 (Neumega®), recombinant B-domain deleted factor VIII (ReFacto®) and recombinant bone morphogenetic protein (BMP-2, INFUSE® Bone Graft). Dr. Schaub has a B.S. from the University of Nevada Las Vegas and a PhD from Washington State University. He has more than 150 peer reviewed publications and he is co-inventor on 8 issued patents.
Santhosh Vadivelu, Ph.D., Inventor & Founder
Santhosh is a patient advocate at heart with a passion to translate science into meaningful clinical products. Recently he was CEO and President of EpiDestiny, a clinical stage biotech company focused in developing rare hematology and oncology therapies. At EpiDestiny, he led and completed $400 million worldwide license agreement with Novo Nordisk.
He has held several cross-functional senior leadership roles during the start-up formation, corporate development, business strategy of several transformative drug development programs at Canaan Partners, Cleveland Clinic. Santhosh received his M.Sc in Lifesciences from the Bharathidasan University, India and completed his Ph.D at Institute of Molecular Pathology, Vienna, Austria and Post Doctoral research with Bruce Stillman at Cold Spring Harbor Laboratory, NY.